AXSM earnings call for the period ending June 30, 2019.
News & Analysis: Axsome Therapeutics
This tiny biotech is racing toward a blockbuster drug launch.
This tiny biotech may have found the tastiest low-hanging fruit the industry's ever seen.
Shares have nearly doubled in March following a string of updates, although there was no news on Monday.
The tiny pharma company splashed onto the radar of investors this week with great trial results, but a maturing drug pipeline has one inescapable downside.
The tiny pharma company reported promising results in a study for its lead drug candidate, eliciting comparisons to a reputable high-flying peer.